Maxalt (Rizatriptan Benzoate) Patent Expiration, LOE Window & CMS Spending

Maxalt (Rizatriptan Benzoate) by Organon: Off-Patent Genericized (AB Competition), 6 AB generics, $1.2M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorOrganon
FDA Application & PathwayN020864 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors6
2024 CMS Total Public Spend$1.2M
2024 Medicare Part D Spend$1.1M
2024 Medicaid Spend$74K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Organon across sibling Meru public-data platforms.